Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review

View ORCID ProfileAgustín Ciapponi, View ORCID ProfileAriel Bardach, Agustina Mazzoni, Tomás Alconada, Steven Anderson, View ORCID ProfileFernando J. Argento, View ORCID ProfileJamile Ballivian, Karin Bok, View ORCID ProfileDaniel Comandé, Emily Erbelding, View ORCID ProfileErin Goucher, View ORCID ProfileBeate Kampmann, Ruth Karron, View ORCID ProfileFlor M. Munoz, María Carolina Palermo, View ORCID ProfileEdward P. K. Parker, View ORCID ProfileFederico Rodriguez Cairoli, María Victoria Santa, View ORCID ProfileAndy Stergachis, Gerald Voss, View ORCID ProfileXu Xiong, Natalia Zamora, Sabra Zaraa, View ORCID ProfileMabel Berrueta, View ORCID ProfilePierre M. Buekens
doi: https://doi.org/10.1101/2021.06.03.21258283
Agustín Ciapponi
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Agustín Ciapponi
  • For correspondence: aciapponi@iecs.org.ar
Ariel Bardach
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ariel Bardach
Agustina Mazzoni
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomás Alconada
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Anderson
2US Food & Drug Administration
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando J. Argento
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fernando J. Argento
Jamile Ballivian
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jamile Ballivian
Karin Bok
3National Institute of Allergy and Infectious Diseases; National Institutes of Health
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Comandé
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel Comandé
Emily Erbelding
4National Institute of Allergy and Infectious Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin Goucher
5School of Public Health and Tropical Medicine, Tulane University, New Orleans, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Erin Goucher
Beate Kampmann
6“The Vaccine Centre, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; Vaccines & Immunity Theme, MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia”
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Beate Kampmann
Ruth Karron
7Bloomberg School of Public Health, Johns Hopkins University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flor M. Munoz
8Baylor College of Medicine; Texas Children's Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Flor M. Munoz
María Carolina Palermo
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward P. K. Parker
9The Vaccine Centre, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edward P. K. Parker
Federico Rodriguez Cairoli
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Federico Rodriguez Cairoli
María Victoria Santa
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andy Stergachis
10School of Pharmacy and School of Public Health, University of Washington, Seattle, WA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andy Stergachis
Gerald Voss
11TuBerculosis Vaccine Initiative (TBVI, Lelystad, The Netherlands)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xu Xiong
5School of Public Health and Tropical Medicine, Tulane University, New Orleans, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xu Xiong
Natalia Zamora
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabra Zaraa
12School of Pharmacy, University of Washington, Seattle, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mabel Berrueta
1Instituto de Efectividad Clinica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mabel Berrueta
Pierre M. Buekens
5School of Public Health and Tropical Medicine, Tulane University, New Orleans, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pierre M. Buekens
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Pregnant women with COVID-19 are at an increased risk of severe COVID-19 illness as well as adverse pregnancy and birth outcomes. Many countries are vaccinating or considering vaccinating pregnant women with limited available data about the safety of this strategy. Early identification of safety concerns of COVID-19 vaccines, including their components, or their technological platforms is therefore urgently needed.

Methods We conducted a rapid systematic review, as the first phase of an ongoing full systematic review, to evaluate the safety of COVID-19 vaccines in pregnant women, including their components, and their technological platforms (whole virus, protein, viral vector or nucleic acid) used in other vaccines, following the Cochrane methods and the PRISMA statement for reporting (PROSPERO-CRD42021234185).

We searched literature databases, COVID-19 and pregnancy registries from inception February 2021 without time or language restriction and explored the reference lists of relevant systematic reviews retrieved. We selected studies of any methodological design that included at least 50 pregnant women or pregnant animals exposed to the vaccines that were selected for review by the COVAX MIWG in August 2020 or their components or platforms included in the COVID-19 vaccines, and evaluated adverse events during pregnancy and the neonatal period.

Pairs of reviewers independently selected studies through the COVIDENCE web software and performed the data extraction through a previously piloted online extraction form. Discrepancies were resolved by consensus.

Results We identified 6768 records, 256 potentially eligible studies were assessed by full-text, and 37 clinical and non-clinical studies (38 reports, involving 2,397,715 pregnant women and 56 pregnant animals) and 12 pregnancy registries were included.

Most studies (89%) were conducted in high-income countries. The most frequent study design was cohort studies (n=21), followed by surveillance studies, randomized controlled trials, and registry analyses. Most studies (76%) allowed comparisons between vaccinated and unvaccinated pregnant women (n=25) or animals (n=3) and reported exposures during the three trimesters of pregnancy.

The most frequent exposure was to AS03 adjuvant in the context of A/H1N1 pandemic influenza vaccines (n=24), followed by aluminum-based adjuvants (n=11). Aluminum phosphate was used in Respiratory Syncytial Virus Fusion candidate vaccines (n=3) and Tdap vaccines (n=3). Different aluminum-based adjuvants were used in hepatitis vaccines. The replication-deficient simian adenovirus ChAdOx1 was used for a Rift Valley fever vaccine. Only one study reported exposure to messenger RNA (mRNA) COVID-19 vaccines that also used lipid nanoparticles. Except for one preliminary report about A/H1N1 influenza vaccination (adjuvant AS03) - corrected by the authors in a more thorough analysis, all studies concluded that there were no safety concerns.

Conclusion This rapid review found no evidence of pregnancy-associated safety concerns of COVID-19 vaccines that were selected for review by the COVAX MIWG or of their components or platforms when used in other vaccines. However, the need for further data on several vaccine platforms and components is warranted given their novelty. Our findings support current WHO guidelines recommending that pregnant women may consider receiving COVID-19 vaccines, particularly if they are at high risk of exposure or have comorbidities that enhance the risk of severe disease.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported, in whole by the Bill & Melinda Gates Foundation [INV008443]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. The sponsors had no role in conducting the present study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Systematic reviews do not require IRB and/or ethics committee approvals

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All relevant data its presented in the manuscript and supplemental files.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 06, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review
Agustín Ciapponi, Ariel Bardach, Agustina Mazzoni, Tomás Alconada, Steven Anderson, Fernando J. Argento, Jamile Ballivian, Karin Bok, Daniel Comandé, Emily Erbelding, Erin Goucher, Beate Kampmann, Ruth Karron, Flor M. Munoz, María Carolina Palermo, Edward P. K. Parker, Federico Rodriguez Cairoli, María Victoria Santa, Andy Stergachis, Gerald Voss, Xu Xiong, Natalia Zamora, Sabra Zaraa, Mabel Berrueta, Pierre M. Buekens
medRxiv 2021.06.03.21258283; doi: https://doi.org/10.1101/2021.06.03.21258283
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Safety of COVID-19 vaccines, their components or their platforms for pregnant women: A rapid review
Agustín Ciapponi, Ariel Bardach, Agustina Mazzoni, Tomás Alconada, Steven Anderson, Fernando J. Argento, Jamile Ballivian, Karin Bok, Daniel Comandé, Emily Erbelding, Erin Goucher, Beate Kampmann, Ruth Karron, Flor M. Munoz, María Carolina Palermo, Edward P. K. Parker, Federico Rodriguez Cairoli, María Victoria Santa, Andy Stergachis, Gerald Voss, Xu Xiong, Natalia Zamora, Sabra Zaraa, Mabel Berrueta, Pierre M. Buekens
medRxiv 2021.06.03.21258283; doi: https://doi.org/10.1101/2021.06.03.21258283

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Obstetrics and Gynecology
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1746)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (651)
  • Epidemiology (10770)
  • Forensic Medicine (8)
  • Gastroenterology (582)
  • Genetic and Genomic Medicine (2930)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1917)
  • Health Policy (832)
  • Health Systems and Quality Improvement (741)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12495)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (319)
  • Neurology (2778)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (553)
  • Occupational and Environmental Health (596)
  • Oncology (1451)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (254)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (378)
  • Pediatrics (863)
  • Pharmacology and Therapeutics (361)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2626)
  • Public and Global Health (5336)
  • Radiology and Imaging (1001)
  • Rehabilitation Medicine and Physical Therapy (592)
  • Respiratory Medicine (721)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (124)